報價延遲最少15分鐘:2025/05/24 21:52 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.21 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-7.22/-3.58
|
|
企業價值
132.62M
|
| 資產負債 |
|
每股賬面淨值
1.26
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
1.00M
|
|
每股收益
0.17
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/24 21:52 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections. |